Updates in Upper GI Cancers From ASCO and ASCO GI 2024 - Episode 2

4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

,

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.